Granisetron transdermal delivery system is effective in the control of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in China.

Chemotherapy-induced nausea and vomiting (CINV) remains the major adverse effect of cancer treatment which impairs patients’ quality of life and affects their compliance with further treatment (1,2).

[1]  J. Ahn,et al.  A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients , 2015, Supportive Care in Cancer.

[2]  S. Grunberg,et al.  Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study , 2010, Supportive Care in Cancer.

[3]  L. Schulmeister.  Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. , 2009, Clinical journal of oncology nursing.

[4]  H. Drenth,et al.  Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting , 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[5]  F. Roila,et al.  Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy , 2003, Health and quality of life outcomes.

[6]  W. Hasler.  Serotonin receptor physiology: relation to emesis. , 1999, Digestive diseases and sciences.

[7]  J. Laszlo.  Nausea and Vomiting as Major Complications of Cancer Chemotherapy , 1983, Drugs.

[8]  A. Fauser,et al.  Anti-Emetics for Cancer Chemotherapy-Induced Emesis Potential of Alternative Delivery Systems , 2012, Drugs.

[9]  P. D,et al.  Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists , 2004, Supportive Care in Cancer.